SIFI Unveils Innovations at Renowned Cataract Surgery Congress

SIFI Unveils Groundbreaking Innovations at Major Congress

SIFI, a premier international ophthalmic company, is excited to announce its participation in an important medical gathering where it will showcase two cutting-edge product innovations along with new scientific evidence. This event, the Congress of The European Society of Cataract and Refractive Surgeons (ESCRS), serves as a platform for sharing advances in cataract and refractive surgery.

Innovative Products Set to Transform Patient Care

As part of its commitment to excellence in healthcare, SIFI is pioneering new technologies that promise to enhance surgical outcomes. Maria Cristina Curatolo, SIFI's Executive Director of Innovation and Medical Science, emphasizes the integration of wavefront technology with ocular surface management, a game-changer in refractive cataract procedures. These developments are designed to help patients achieve superior vision quality.

New Intraocular Lens Innovations

SIFI will introduce a revamped version of its EVOLUX extended monofocal intraocular lens (IOL), which boasts improved delivery technology. Surgeons will benefit from the flexibility of employing either a push or screw technique during implantation.

Advanced IOL Calculator

In addition, a new IOL calculator utilizing Hoffer QST and Næser-Savini formulas will improve the precision in calculating both spherical and cylindrical lens powers, enhanced by artificial intelligence applications.

Scientific Presentations Highlight Clinical Outcomes

The Congress will feature five podium presentations and an equal number of e-Posters focusing on SIFI’s solutions for cataract surgery and ocular surface diseases. Among these presentations, topics include the performance of the EVOLUX lens and the presbyopia-correcting WELL FUSION system, as well as the benefits of Eyestil SYNFO artificial tears.

Podium Sessions Overview

On Sunday, a series of e-Poster presentations will cover various aspects of visual performance and patient satisfaction across different IOLs and treatments. Notable studies include:

• Comparative studies on visual acuity with monofocal IOLs (Pagnacco C.)
• Investigative research on preservative-free ophthalmic solutions for eye discomfort (Molero-Senosiain M.)
• Refractive outcomes following the use of enhanced monofocal lenses (Romualdi G.)
• Visual acuity assessments of non-diffractive lens technologies (Rotter A.)

Free Paper Session Details

A pivotal free paper session is scheduled, focusing on a randomized clinical trial comparing the effectiveness of extended depth of focus IOLs against trifocal IOLs, providing insights into patient quality of life post-surgery (Pagnacco C.).

Satellite Symposium Announcements

On a separate note, SIFI is organizing a Satellite Symposium titled "Ultimate Vision: Mastering Sight with Wavefront Engineering and Innovative Ocular Surface Management," which will feature leading experts in the field discussing the latest advancements.

Comprehensive List of e-Posters

In addition to podium presentations, attendees can look forward to a variety of e-Posters, including research on:

• Outcomes of enhanced monofocal IOLs (Savini G.)
• Long-term visual performance of EVOLUX lenses post-cataract surgery (Caparas V.)
• Comparative studies on advanced monofocal IOLs from SIFI (Gabri? K.)
• Insights on binocular vision impacts from different intraocular lens technologies (Castanera D.)
• Clinical validation related to wavefront engineering technology (Vacalebre M.)

About SIFI

Founded in 1935, SIFI is a leader in ophthalmic innovation, with a robust integrated model encompassing research, development, manufacturing, and commercialization within the pharmaceutical and biomedical sectors. Our mission is to enhance lives through meaningful eye care innovations. SIFI operates in over 40 countries, with a firm footprint in major European markets, Mexico, and partnerships in China and the United Arab Emirates.

Frequently Asked Questions

What is the significance of SIFI's presence at the ESCRS Congress?

SIFI's presence at the Congress highlights its commitment to advancing cataract surgery and enhancing patient care through innovative technologies and research findings.

What new products will SIFI introduce?

SIFI will present an upgraded version of its EVOLUX intraocular lens and a new IOL calculator, both aimed at improving surgical precision and outcomes.

When will the scientific presentations take place?

The presentations will occur on various dates during the Congress, with a specific slate scheduled for Sunday and Tuesday.

What are some of the key topics covered in the presentations?

Topics include visual performance, patient satisfaction, outcomes of different IOL technologies, and treatments for ocular surface diseases.

How can the public learn more about SIFI's innovations?

More information can be found on SIFI's official website, which details their products, research, and ongoing commitments to eye care innovation.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.